Insights
Search Results
Client Highlights
6.03.26
Wilson Sonsini Advises Asana on Acquisition of StackAI
On May 28, 2026, Asana, Inc., the operating system for human-agent teams, announced that it has completed the acquisition of StackAI, a no-code AI workflow platform that enables companies to design, test, deploy, and govern custom AI agents and intelligent automation of business-critical workflows. Wilson Sonsini Goodrich & Rosati advised Asana on the transaction.
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
The StackAI platform connects workflows, data, and actions across enterprise systems such as ERP, CRM, and ITSM to automate operational processes like customer support, IT service requests, compliance workflows, and broader cross-functional business operations. Based in San Francisco, the company has built an impressive track record with customers across financial services, healthcare, and professional services—industries that demand the highest security, reliability, and enterprise-grade governance. Bringing StackAI and Asana together pairs cross-system execution with the platform where teams already plan and run their work alongside the context, ownership, and history of every project.
The Wilson Sonsini team that advised Asana on the transaction was led by Rich Mullen and Kaleigh Hawkins-Schulz and also included:
Client Highlights
5.05.26
Wilson Sonsini Advises Lattice Semiconductor on $1.65 Billion Acquisition of AMI
On May 4, 2026, Lattice Semiconductor announced it has entered into a definitive agreement with THL Partners to acquire AMI, a leader in platform firmware and infrastructure manageability for cloud and AI. The planned acquisition advances Lattice Semiconductor’s strategy to expand its position in server, AI, and cloud applications spanning hardware, security, manageability, and control. Wilson Sonsini Goodrich & Rosati is advising Lattice Semiconductor on the transaction.
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
3.27.26
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Alerts
3.03.26
Reporting Season Alert: Five Key Considerations for Proxy Season
With the 2026 proxy season upon us, companies are finalizing annual meeting materials against a backdrop of shifting investor priorities, evolving engagement dynamics, and regulatory uncertainty. This alert highlights governance, disclosure, and engagement considerations for companies preparing for their 2026 annual meetings.1 Below are five key considerations as you finalize preparations.
Client Highlights
2.26.26
Wilson Sonsini Advises Eventus on Majority Investment by Terminus Capital Partners
On February 26, 2026, Terminus Capital Partners (TCP), a growth‑oriented private equity firm focused on majority investments in B2B software companies, and Eventus, a leading provider of comprehensive, at-scale trade surveillance and financial risk solutions, announced that TCP has acquired majority control in Eventus, positioning the firm for accelerated geographical expansion and growth in its product offerings. Wilson Sonsini Goodrich & Rosati advised Eventus on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Alerts
12.03.25
ISS Releases 2026 Benchmark Policy Updates
On November 25, 2025, ISS Governance announced the release of its 2026 Benchmark Policy Updates, which will apply to shareholder meetings on or after February 1, 2026. Set forth below are key changes for U.S. companies. The full 2026 Benchmark Policy document and updated FAQs, which often provide additional details regarding the policy changes, are expected to be published and available on ISS’s website by mid-December.
Client Highlights
11.05.25
Wilson Sonsini Advises Chilldyne on Acquisition by Daikin Applied
On November 4, 2025, Daikin Applied Americas Inc., the world’s number one air conditioning company, closed its acquisition of Chilldyne, Inc., an experienced leader in negative pressure liquid cooling systems for high-performance and AI data centers. Wilson Sonsini Goodrich & Rosati advised Chilldyne on the transaction.